Navigation Links
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Date:9/17/2007

l studies with G4544 will be to establish its bioequivalence with the intravenous product, potentially enabling rapid regulatory approval of the oral formulation. Genta holds or has exclusively licensed the intellectual property related to G4544.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or produc
'/>"/>

SOURCE Genta Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
7. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
8. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Calif. and ST. LOUIS ... high blood pressure or high cholesterol may achieve better ... performance-based networks, according to early results of a unique ... (NASDAQ: ESRX ). "Pharmacists are one ... their frequent interactions with our members presents enormous opportunities ...
(Date:5/5/2015)... Lymphatic pump treatment (LPT) shows promise in ... a new study published in The Journal of ... performed LPT on infected rats three times a day ... to treat pneumonia. After 96 hours, over 60 percent ... 25 percent of rats who received levofloxacin alone. ...
(Date:5/5/2015)... , May 5, 2015 Big Market Research ... US, Europe , ( France , ... Spain , UK) and Japan . ... reviewed. The report provides the 5-year test volume and sales forecasts ... NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ...
Breaking Medicine Technology:SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 4Lymphatic Pump Treatment Enhances Antibiotic Effectiveness for Treating Pneumonia 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3
(Date:5/5/2015)... Scottsdale, AZ (PRWEB) May 05, 2015 ... NCPDP’s Elite Partner Program. The program establishes a three-year ... to a maximum of 10 Elite Partners. “AmerisourceBergen has ... Ann Stember, President of NCPDP, “and this is a ... work. , We can trace AmerisourceBergen back to ...
(Date:5/5/2015)... 05, 2015 AxoGen, Inc. (NASDAQ: ... the $1.6 billion peripheral nerve repair market, reported record ... March 31, 2015 compared to $3.14 million in the ... of our proprietary portfolio of nerve repair products ... Nerve Protector – and our solid sales execution delivered ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Health IVF Clinic in Greece, an experienced team ... and treatment of infertility for patients around the globe. ... partnered with VisitandCare.com. Greece unquestionably remains a global leader ... most talented and hard-working fertility specialists in the world ...
(Date:5/5/2015)... May 05, 2015 The global lab ... 2020 from $3,474.2 Million in 2014, at an estimated ... segments the lab automation market on the basis of ... and region. On the basis of application, Lab Automation ... solutions, and proteomics solutions. Drug discovery is a major ...
(Date:5/5/2015)... York, New York (PRWEB) May 05, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on behalf ... complications due to their use of prescription ... in the federal multidistrict litigation underway in ... According to court documents dated May 1st, ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4
... 5, 2008 The American Cancer Society, the American ... Force on Colorectal Cancer (a group that comprises ... Gastroenterological Association, and American Society for Gastrointestinal Endoscopy) ... colorectal cancer screening. The guidelines add two new ...
... child,has a chronic illness is never easy, especially when ... it comes to physical,activities for children, most parents prefer ... experts say that may be a mistake. The spring ... Lupus Now(R), reports,that once a child,s lupus has been ...
... 5 Relax The Back corporation,sold a record number ... 16 franchised locations were sold last year, and 12 ... to deliver similarly,strong franchise sales results, with four stores ... another nine scheduled to open by June. The,company,s long-term ...
... Biopharmaceuticals using innovative technology in study of ... anti-infective ... today announced it has achieved another major milestone,in the management of ... The milestone EDC trial is a Phase II study being ...
... who rely on Community and Mission Hospital of Huntington ... go elsewhere as the,facility shuts its doors., The ... Mission. No new patients will be admitted and about ... its urgent care operations,last year., The Huntington Park ...
... decode the mind for therapeutic purposes , , WEDNESDAY, March 5 ... report they have found a way to "read" visual activity ... to scan the brain for activity information related to the ... of brain activity-image links is then created, so that future ...
Cached Medicine News:Health News:Health groups issue updated colorectal cancer screening guidelines 2Health News:Health groups issue updated colorectal cancer screening guidelines 3Health News:Child's Play - Lupus Now(R) Magazine Explores Activities for Children With a Chronic Condition 2Health News:Relax The Back Announces Record Growth in 2007; Executives Bullish on Specialty Retailer's Prospects for 2008 2Health News:Quintiles Data Management Surpasses 300 EDC Trials 2Health News:Community & Mission Hospital of Huntington Park Shutting Down Mission Campus, Terminating Workers 2Health News:Brain Scans Let Computer 'Read' Visual Activity 2Health News:Brain Scans Let Computer 'Read' Visual Activity 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: